Prof. Peter Collins, Prof. Giuseppe Mancia, Prof. Carolyn Lam, Dr. Choo Gim Hooi, 20170712103633
Coronary artery disease (CAD) is the leading cause of death worldwide
and is expected to remain so for the foreseeable future due to both the
ageing population and the increasing prevalence of risk factors such as
hypertension, dyslipidaemia, and diabetes. CAD is also the primary risk
factor in the development of heart failure (HF). At the 2nd Asia Pacific
CardioConnect Meeting in Hong Kong sponsored by Menarini, a group of
international and regional experts discussed current strategies for
managing stable CAD and HF and highlighted areas where patient outcomes
may be improved.
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
anti-inflammatory drugs (NSAIDs) are widely used to treat pain and
inflammation in patients with arthritis, but the vascular effects of some
NSAIDs have cast doubt on whether they can be used in patients at risk for
cardiovascular (CV) disease. At the American Heart Association’s Scientific
Sessions 2016 held recently in New Orleans, Louisiana, US, Professor Steven
Nissen of the Cleveland Clinic in Cleveland, Ohio, US, presented latest data
from the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated
Safety vs Ibuprofen or Naproxen) trial that evaluated the CV risk and safety
profile of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib vs
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
At the recent launch of an exclusive guidebook on vasodilating β-blockers for the treatment of hypertension and chronic heart failure (HF), Professor Athanasios J. Manolis delivered a lecture on why nebivolol is different from the other agents in its class.
During the 8th Diabetes Complications Conference & Grand Rounds 2016, Dr Azani Mohamed Daud talked about the guidelines on the use of ACEIs and ARBs in hypertension, and highlighted their clinical efficacies for hypertension treatment.
Prof. Abdul Rashid, Prof. Martin Strauss, Prof. Alistair Hall, 20161212084416
Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
The addition of evolocumab to statin therapy in individuals with angiographic coronary disease appeared to encourage coronary atherosclerosis regression, as demonstrated in the GLAGOV* trial presented at the Scientific Sessions of the American Heart Association (AHA 2016) held in New Orleans, Louisiana, US.
In targeted temperature management (TTM) postcardiac arrest, tighter temperature control is achieved with internal than external cooling, a study has shown. Moreover, internal cooling potentially results in better survival-to-hospital discharge outcomes and reduces cardiac arrhythmia complications in carefully selected patients as compared with normothermia.
A new high-sensitivity troponin I assay with a lower cut-off substantially shortens triage time to 1 hour and reduces mortality for patients presenting to emergency departments with chest pain, a study presented at the European Society of Cardiology (ESC) Congress 2015 in London, UK has shown.